PHARMACEUTICAL MICROBIOLOGY

Reclassification of Pharmaceutical Microorganisms: Implications for Quality Control and Drug Safety Reclassification of Pharmaceutical Microorganisms: Implications for Quality Control and Drug Safety The field of pharmaceutical microbiology is continuously evolving, with advances in molecular techniques and genomic studies leading to the reclassification of several microorganisms quality control (QC) , regulatory compliance, and ensuring the safety of pharmaceutical products . 🔬 What is Microbial Reclassification? Microbial reclassification refers to the process of updating the taxonomy or naming of microorganisms based on new scientific evidence, often derived from: 16S rRNA gene sequencing Whole-genome sequencing Phylogenetic and biochemical analysis In pharmaceuticals, this has significant consequences, as regulatory documents, QC protocols, and compendial references often depend on correct microbial nomenclature. ⚖️ Common Examples of Reclassifi...

Bacillus subtilis Reclassified as Bacillus spizizenii: Implications and Insights in Microbiology Bacillus subtilis has been a cornerstone of microbiology research, industrial applications, and educational studies for decades. Recently, taxonomic studies have led to its reclassification as Bacillus spizizenii . This update reflects modern phylogenetic understanding and has significant implications in microbiology, biotechnology, and industrial processes. 🔬 Historical Background of Bacillus subtilis Bacillus subtilis, first described in the 19th century, is a gram-positive, rod-shaped, endospore-forming bacterium. It is widely recognized for: Its ability to form resilient spores under unfavorable conditions Its use as a model organism in genetics and molecular biology Industrial applications, including enzyme production, probiotics, and fermentation Due to advances in molecular taxonomy and genome sequencing, scientists identified distinct phylogenetic diffe...